Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) EBT (2016 - 2025)

Historic EBT for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $34.3 million.

  • Amicus Therapeutics' EBT rose 40514.37% to $34.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 10728.9%. This contributed to the annual value of -$28.8 million for FY2024, which is 8084.22% up from last year.
  • As of Q3 2025, Amicus Therapeutics' EBT stood at $34.3 million, which was up 40514.37% from -$19.2 million recorded in Q2 2025.
  • Amicus Therapeutics' EBT's 5-year high stood at $34.3 million during Q3 2025, with a 5-year trough of -$81.5 million in Q1 2022.
  • Moreover, its 5-year median value for EBT was -$40.5 million (2023), whereas its average is -$35.0 million.
  • Data for Amicus Therapeutics' EBT shows a peak YoY increase of 40514.37% (in 2025) and a maximum YoY decrease of 1786018.52% (in 2025) over the last 5 years.
  • Amicus Therapeutics' EBT (Quarter) stood at -$80.3 million in 2021, then increased by 12.72% to -$70.1 million in 2022, then surged by 54.82% to -$31.7 million in 2023, then soared by 125.06% to $7.9 million in 2024, then soared by 331.99% to $34.3 million in 2025.
  • Its last three reported values are $34.3 million in Q3 2025, -$19.2 million for Q2 2025, and -$18.0 million during Q1 2025.